WO2011134599A3 - Quantitative markers for determining the mental status of a test subject - Google Patents

Quantitative markers for determining the mental status of a test subject Download PDF

Info

Publication number
WO2011134599A3
WO2011134599A3 PCT/EP2011/001804 EP2011001804W WO2011134599A3 WO 2011134599 A3 WO2011134599 A3 WO 2011134599A3 EP 2011001804 W EP2011001804 W EP 2011001804W WO 2011134599 A3 WO2011134599 A3 WO 2011134599A3
Authority
WO
WIPO (PCT)
Prior art keywords
test subject
mental status
determining
proteins
markers
Prior art date
Application number
PCT/EP2011/001804
Other languages
German (de)
French (fr)
Other versions
WO2011134599A2 (en
Inventor
Carsten Korth
Original Assignee
Carsten Korth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carsten Korth filed Critical Carsten Korth
Publication of WO2011134599A2 publication Critical patent/WO2011134599A2/en
Publication of WO2011134599A3 publication Critical patent/WO2011134599A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to quantitative markers for determining the mental status of a test subject, the markers comprising proteins the degree of concentration of which can be determined. The proteins are identified by an antibody with the designation AK 4DC1, and the concentration of said proteins in tissue samples of a test subject enables a rating of the mental status in the test subject. The concentration of at least one of the marker proteins in tissue samples of healthy test subjects is significantly higher than in unaffected test subjects.
PCT/EP2011/001804 2010-04-28 2011-04-12 Quantitative markers for determining the mental status of a test subject WO2011134599A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201010018561 DE102010018561B4 (en) 2010-04-28 2010-04-28 Quantitative markers for determining the mental status of a subject
DE102010018561.2 2010-04-28

Publications (2)

Publication Number Publication Date
WO2011134599A2 WO2011134599A2 (en) 2011-11-03
WO2011134599A3 true WO2011134599A3 (en) 2012-01-19

Family

ID=44118711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/001804 WO2011134599A2 (en) 2010-04-28 2011-04-12 Quantitative markers for determining the mental status of a test subject

Country Status (2)

Country Link
DE (1) DE102010018561B4 (en)
WO (1) WO2011134599A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099995A2 (en) * 2002-05-24 2003-12-04 Merck & Co., Inc. Murine ortholog of the human disrupted-in-schizophrenia 1 gene
WO2005077978A2 (en) * 2004-02-13 2005-08-25 Heinrich-Heine-Universität Düsseldorf Antibody for diagnosing and treating neuropsychiatric diseases, in particular schizophrenia, depression and bipolar affective disorders
US20050255500A1 (en) * 2004-01-28 2005-11-17 Johns Hopkins University Method for diagnosing or predicting susceptibility to psychiatric disorders
WO2009118151A1 (en) * 2008-03-26 2009-10-01 Carsten Korth Method for diagnosing and treating chronic psychiatric illnesses and markers and targets for such methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054345A1 (en) 2001-01-24 2003-03-20 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of neuropsychiatric disorders, including schizophrenia
WO2004071269A2 (en) 2003-02-13 2004-08-26 Intellectual Property Consulting Inc. Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099995A2 (en) * 2002-05-24 2003-12-04 Merck & Co., Inc. Murine ortholog of the human disrupted-in-schizophrenia 1 gene
US20050255500A1 (en) * 2004-01-28 2005-11-17 Johns Hopkins University Method for diagnosing or predicting susceptibility to psychiatric disorders
WO2005077978A2 (en) * 2004-02-13 2005-08-25 Heinrich-Heine-Universität Düsseldorf Antibody for diagnosing and treating neuropsychiatric diseases, in particular schizophrenia, depression and bipolar affective disorders
WO2009118151A1 (en) * 2008-03-26 2009-10-01 Carsten Korth Method for diagnosing and treating chronic psychiatric illnesses and markers and targets for such methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARSTEN KORTH: "DISCopathies: brain disorders related to DISC1 dysfunction", REVIEWS IN NEUROSCIENCE, 1 January 2009 (2009-01-01), pages 321 - 330, XP055003321 *
HARRISON P J ET AL: "SCHIZOPHRENIA GENES, AND GENE EXPRESSION, AND NEUROPATHOLOGY: ON THE MATTER ON THEIR CONVERGENCE", MOLECULAR PSYCHIATRY, BASINGSTOKE, GB, vol. 10, no. 1, 1 January 2005 (2005-01-01), pages 40 - 68, XP009061024, ISSN: 1359-4184, DOI: DOI:10.1038/SJ.MP.4001558 *
LELIVELD S RUTGER ET AL: "Insolubility of disrupted-in-schizophrenia 1 disrupts oligomer-dependent interactions with nuclear distribution element 1 and is associated with sporadic mental disease", JOURNAL OF NEUROSCIENCE, THE SOCIETY, WASHINGTON, DC, US, vol. 28, no. 15, 9 April 2008 (2008-04-09), pages 3839 - 3845, XP009103840, ISSN: 1529-2401, DOI: DOI:10.1523/JNEUROSCI.5389-07.2008 *
NICHOLAS J BRANDON ET AL: "Understanding the Role of DISC1 in Psychiatric Disease and during Normal Development", THE JOURNAL OF NEUROSCIENCE, 14 October 2009 (2009-10-14), pages 12768 - 12775, XP055003316, Retrieved from the Internet <URL:http://www.jneurosci.org/content/29/41/12768.full.pdf> [retrieved on 20110721] *
RUTGER S LELIVELD ET AL, 7 July 2009 (2009-07-07), XP055003143, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdfplus/10.1021/bi900901e> [retrieved on 20110720] *

Also Published As

Publication number Publication date
DE102010018561B4 (en) 2012-04-12
DE102010018561A1 (en) 2011-11-03
WO2011134599A2 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
PH12016501036A1 (en) Il-1 binding proteins
EA201590027A1 (en) DETECTION METHODS OF DISEASES OR CONDITIONS
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
BRPI1007321A2 (en) methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
BRPI1013688A8 (en) IL-17 BINDING PROTEINS.
WO2011015602A3 (en) Lung cancer biomarkers
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
WO2013052505A3 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
WO2014074835A3 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
WO2013032953A3 (en) Development and use of fluorescent probes of unbound bilirubin
WO2011156734A3 (en) Method of characterizing vascular diseases
BR112016004324A2 (en) antibodies
BR112014031958A2 (en) bag3 as tissue marker and biochemical serum
WO2015014794A8 (en) Use of alpha-crystallin b (cryab) in the assessment of heart failure
WO2012082742A3 (en) Detecting cancer with anti-ccl25 and anti-ccr9 antibodies
ES2578477T3 (en) ASC as a marker of chronic obstructive pulmonary disease (COPD)
MX359376B (en) Method and kit for determination of free copper in serum.
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
WO2012145516A3 (en) Methods and kits for quantitative determination of total organic acid content in a coolant
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2014117680A3 (en) Use of trpc6 mrna levels in peripheral blood cells for early detection/diagnosis of senile dementia
BR112012028010A2 (en) isolated antibody, cell, isolated nucleic acid, method of identifying a first antibody that binds to a tat425 antigenic epitope attached to an antibody, methods of inhibiting cell growth, therapeutic treatment of determining the presence of a tat425 protein and diagnosing the presence of a tumor in a mammal
WO2011163627A3 (en) Organ specific diagnostic panels and methods for identification of organ specific panel proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11721227

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11721227

Country of ref document: EP

Kind code of ref document: A2